MacuTest Website for Personalized AMD Risk Prediction and Prevention

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Dec 28, 2022

Keywords

ClinConnect Summary

AMD is the leading cause of blindness in industrialized countries. Current treatments only address the neovascular form and do not always prevent vision loss. This multifactorial pathology involves both genetic factors (more than 50 loci identified) and environmental factors. The genes identified suggest an important contribution of inflammation and innate immunity as well as lipid metabolism in the physiopathology of AMD. As a potential target for preventive actions, the role of lifestyle has also been the subject of much work. Thus, epidemiological studies have identified smoking as an im...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 65 years and older of European geographic origin
• • Presence of early signs of AMD (drusen and/or pigment abnormalities) and/or parents with advanced AMD.
• • Absence of any advanced form of AMD (atrophic or neovascular AMD).
• • Patient who can read, understand and speak French.
• • Patient with access to the MacuTest internet platform throughout the study (telephone, tablet, computer).
• • Patient with the ability and willingness to carry out all planned visits and assessments.
• • Patient with health insurance.
• • Signed informed consent.
• Exclusion Criteria:
• • Presence of a severe ocular pathology that prevents an examination of the fundus.
• • Patient with a history of a medical condition that, in the opinion of the investigator, would prevent the completion of scheduled study visits and completion of the study.
• • Adult under legal protection or residing in a health or social institution.